ARNI linked with reduced risk of all-cause mortality in patients with HFrEF or HFmrEF: Study
Written By : Medha Baranwal
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2022-12-12 05:15 GMT | Update On 2022-12-12 06:53 GMT
Advertisement
Sweden: Patients with heart failure with reduced (HFrEF) or mildly reduced EF (HFmrEF) who received ARNI according to the guideline-led Swedish clinical practice are at reduced risk of all-cause mortality versus ACEi/ARB, a recent study has shown.
The study's findings, published in the Clinical Research in Cardiology, align with the mortality results of the randomized trial, PARADIGM-HF. However, no difference was seen in the hospitalization rate in real-world treatment with angiotensin receptor–neprilysin inhibitor (ARNI) versus angiotensin receptor blocker/angiotensin-converting enzyme inhibitor(ACEi/ARB) in Sweden.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.